


You got
WHAT?



Sífilis congénita: una oportunidad en la prevención

Pablo J. Sánchez, MD
Nationwide Children's Hospital
The Ohio State University
Columbus, OH

7° Congreso Argentino de Infectología Pediátrica
Córdoba, Argentina
April 3-5, 2014

EPIDEMIOLOGY

- ◆ **Worldwide:**
 - Latin America, Africa, Europe
- ◆ **United States:**
 - Racial and ethnic minorities: Blacks
 - South (48%); urban areas
 - Young, unmarried women: lower SEC
 - Congenital cases: inadequate prenatal care
 - Increase in adults since 2001—increase in congenital cases up to 2008, decrease since (322 cases in 2012)



CONGENITAL SYPHILIS: MORTALITY 1992-1998

- ◆ 14,627 cases of CS (78% decline): 942 deaths, 760 stillbirths
- ◆ Case fatality rate: 6.4% (stable)
- ◆ 87% of deaths: untreated, inadequately treated, or undocumented treatment during pregnancy
- ◆ Less prenatal care: ↑ risk of death
- ◆ 52% of deaths occurred by 30 wks of gestation




DIAGNOSTIC STRATEGIES FOR CONGENITAL SYPHILIS

◆ IgM immunoblot:



◆ Polymerase chain reaction (PCR)

◆ Rabbit infectivity test (RIT):



DIAGNOSTIC STRATEGIES FOR CONGENITAL SYPHILIS


- ◆ Vertical transmission
- ◆ “Asymptomatic” newborn
- ◆ Central nervous system invasion
- ◆ Evidence-based rationale for the management of infants born to mothers with reactive serologic tests for syphilis (CDC, AAP)

CONGENITAL SYPHILIS: VERTICAL TRANSMISSION

- ◆ *In utero*: transplacental route following maternal spirochetemia
- ◆ Intrapartum: contact with genital lesion
- ◆ Increases as stage of pregnancy advances but can occur at any time in gestation
- ◆ Related to stage of maternal syphilis

SYPHILIS IN PREGNANCY: THE PARKLAND EXPERIENCE (1988-1998)

			Early Latent	Late Latent
No. of Mothers			145	27
Outcome (%):				
Stillbirth			31 (21)	1 (4)
Congenital Syphilis			21 (14)	1 (4)
Total	6 (23)	32 (60)	52 (36)	2 (7)






STD

Treatment Guidelines

2010

www.cdc.gov




***Evaluation and Treatment
of Infants During the
First Month of Life***

***SCENARIO 1:
PROVEN OR HIGHLY PROBABLE
SYPHILIS***

PROVEN OR HIGHLY PROBABLE SYPHILIS

- ◆ Infant physical exam abnormal
- ◆ Serum VDRL/RPR ≥ 4 x maternal titer
- ◆ Positive darkfield or fluorescent antibody test of body fluid(s)





- ◆ **Histopathology:** necrotizing funisitis, villous enlargement, acute villitis
- ◆ **Increased detection** of congenital syphilis from 67% to 89% in live-born infants, and 91% to 97% in stillborns (Obstet Gynecol 2002;100:126)

EARLY CONGENITAL SYPHILIS: CLINICAL MANIFESTATIONS


- ◆ Hepatosplenomegaly
- ◆ Anemia
- ◆ Thrombocytopenia
- ◆ Hydrops fetalis
- ◆ Pneumonia
- ◆ Nephrotic syndrome







Pituitary Mass




PROVEN OR HIGHLY PROBABLE SYPHILIS: EVALUATION

- ◆ **Lumbar puncture, CBC / platelet count**
- ◆ **Bone X-rays:**
 - **CDC: as clinically indicated**
 - **AAP: unless the diagnosis has been otherwise established**
- ◆ **Other tests (eye exam, LFTs, HUS, ABR, CXR) as clinically indicated**

PROVEN OR HIGHLY PROBABLE SYPHILIS: BONE X-RAYS

- ◆ Periostitis
- ◆ Osteochondritis
- ◆ Frequently abnormal:
65% (Houston/Dallas)
- ◆ Abnormal findings
do not change
therapy



PROVEN OR HIGHLY PROBABLE SYPHILIS: EVALUATION

- ◆ **Lumbar puncture:**
 - **Why? To establish a baseline for follow-up**
 - **Why not?**

CENTRAL NERVOUS SYSTEM INFECTION IN CONGENITAL SYPHILIS

76 INFANTS, **CSF RIT**: 17 POS, 59 NEG

◆ Sensitivity; Specificity:

Reactive CSF VDRL: 53%; 90%

CSF Pleocytosis: 38%; 88%

Elevated CSF Protein: 56%; 78%

Michelow et al. NEJM, 2002

CONGENITAL SYPHILIS: *SYMPTOMATIC* INFANTS

	SERUM/BLOOD (n=46)	CSF (n=39)
POS IgM	98%	41%
POS RIT	57% (20/35)	47% (16/34)

CONGENITAL SYPHILIS: TREATMENT

- ◆ Infant VDRL/RPR $\geq 4x$ Maternal VDRL/RPR OR Physical Exam is *ABNORMAL* OR \oplus TP body fluid:
 - Aqueous PCN G 50,000 U/kg IV q 8-12 hr x 10 d, or
 - Procaine PCN G 50,000 U/kg IM q day x 10 d

SCENARIO 2



**The “ASYMPTOMATIC” infant: Why?
What is the likelihood that this infant has
congenital syphilis?**

CONGENITAL SYPHILIS: ASYMPTOMATIC INFANTS BORN TO MOTHERS WITH UNTREATED SYPHILIS

	SERUM/BLOOD (n=86)	CSF (n=68)
POS IgM	16%	3% (2/62)
POS RIT	7%	2% (1/62)

MATERNAL TREATMENT ≤ 4 WKS BEFORE DELIVERY: ASYMPTOMATIC INFANTS

	Blood	CSF
No. of Infants:	23*	21*
⊕ IgM	30%	5%
⊕ RIT	5%	0/19

* 1 Mother HIV-Ab ⊕

CONGENITAL SYPHILIS: EVALUATION AND TREATMENT

◆ Infant physical exam normal AND
VDRL/RPR <4x maternal titer:

– **Maternal Rx:**

- None, inadequate, unknown
- Erythromycin, azithromycin,
non-penicillin drug
- ≤ 4 wks before delivery

– Mother re-infected (RPR \uparrow 4x)

CONGENITAL SYPHILIS: “*Asymptomatic*” INFANT

- ◆ Physical exam normal; VDRL/RPR reactive and <4x maternal titer (cont):
 - **Evaluation:** CBC, platelets, LP, bone X-rays
 - **Treatment: options**
 - **Penicillin G** (aqueous/procaine) x 10d: evaluation optional; evaluation abnormal, not done or incomplete
 - **Benzathine PCN G** 50,000 u/kg IM: normal CBC, platelet, lumbar puncture, bone x-rays and follow-up certain

CONGENITAL SYPHILIS: “*Asymptomatic*” INFANT

- ◆ Physical Exam NORMAL and serum VDRL/RPR **nonreactive** (cont):
 - **Evaluation:** none (no CBC, x-rays, LP)
 - **Treatment:**
 - **Benzathine PCN G 50,000 u/kg IM**

SCENARIO 3

CONGENITAL SYPHILIS

- ◆ Infant physical exam normal AND VDRL/RPR <4x maternal titer:
 - **Maternal Rx:**
 - During pregnancy, appropriate for stage of infection, > 4 wks before delivery
 - No evidence of reinfection or relapse

CONGENITAL SYPHILIS: “ASYMPTOMATIC” INFANT

- ◆ No evaluation

- ◆ Treatment:

- Benzathine penicillin G IM x 1

- “some experts” would not treat but provide close serologic follow-up

- AAP: follow-up preferably monthly, until RPR NR

Special Considerations

- ◆ **Penicillin allergy: desensitize, data insufficient to recommend other agents, but if nonpenicillin agent used, close serologic and CSF follow-up**
- ◆ **HIV infection: infants born to mothers coinfectd with HIV do not require different evaluation, therapy, or follow-up for syphilis**
- ◆ **Penicillin shortage: penicillin G, procaine penicillin, benzathine penicillin, ceftriaxone**
[www.cdc.gov.nchstp/dstd/penicillinG.htm/](http://www.cdc.gov/nchstp/dstd/penicillinG.htm/)

CONGENITAL SYPHILIS: FOLLOW-UP

- ◆ Serologic testing (RPR) q 2-3 months until nonreactive. Persistent, stable titer beyond 1 yr: retreat?
- ◆ Treponemal test: Reactive beyond 18 months indicates congenital infection
- ◆ Initial CSF abnormal: Repeat at 6 months and if abnormal, retreat

CONGENITAL SYPHILIS: PREVENTION


- ◆ Ensure adequate universal prenatal care
- ◆ Serologic screening (RPR) at 1st prenatal visit; repeat at 28-32 wks, delivery in high-risk areas
- ◆ Screening with treponemal test?

“REVERSE SEQUENCE” SCREENING

MMWR, 2/2011

- ◆ 5 laboratories in USA
- ◆ 140,176 sera screened with treponemal EIA/CIA
- ◆ 3.4% (4834) had reactive test result
- ◆ 57% (2743/4834): RPR nonreactive
- ◆ **32%** (866/2743) NR by TP-PA or FTA-ABS – initial EIA/CIA false-positive?
- ◆ Discordant results (NR TP-PA/FTA-ABS) were almost 3x more frequent in low vs high prevalence populations (41% vs. 14%)

“REVERSE SEQUENCE” SCREENING: CDC RECOMMENDATIONS



MMWR, 2/2011

CONGENITAL SYPHILIS: PREVENTION

- ◆ **Do not discharge infant without maternal serologic status documented at least once during pregnancy**
- ◆ **Report all cases to Health Dept. for contact tracing and identification of core populations and environments**





ELIMINATE X SYPHILIS
1-888-4EZ-CURE